ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right now Image courtesy of ResMed ResMed CEO Mick Farrells stance on the issue is that the latest advances in both Big Tech and Big Pharma can potentially bring incredible numbers of new patients into the healthcare system where ResMed is uniquely positioned to provide ongoing care at home. Patients are voting with their wallets and respiratory therapists and physicians are voting with their recommendations and their prescriptions. During the companys first-quarter earnings call, Farrell said the company is laser-focused on growing the market to help people get on the therapy they need and on a pathway to better sleep, better health, and better long-term care
Oral formulations of GLP-1 drugs, like oral Semaglutide, offer the convenience of daily administration without the need for injections, making them more appealing to individuals who are averse to needles
For individuals in research studies focusing on type 2 diabetes, this stability has been associated with improved HbA1c scores and reduced glucose variability
Its balanced blend supports vital bodily functions, making it an excellent addition to your daily wellness routine
Based on Truveris' book of business, GLP-1 utilization has more than doubled since 2023, rising from 5% to 13% of all utilizers
That's why a medically supervised weight loss program with semaglutide can be so helpful they provide professional guidance and support to help you reach your goals